Literature DB >> 19255857

Antidrug antibody assay validation: industry survey results.

Boris Gorovits1.   

Abstract

Immunogenicity of biopharmaceutical products has attracted considerable attention from the industrial, academia, and regulatory organizations. Many methods exist to detect and characterize level of antidrug antibody response in patients. Still, additional work is required to harmonize various approaches used throughout the industry. This review presents results of a survey sponsored by the American Association of Pharmaceutical Scientists that was designed to collect relevant information and to understand various methods used throughout the bioanalytical field for the detection and evaluation of antidrug antibody responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255857      PMCID: PMC2664891          DOI: 10.1208/s12248-009-9091-6

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  14 in total

1.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.

Authors:  J W Findlay; W C Smith; J W Lee; G D Nordblom; I Das; B S DeSilva; M N Khan; R R Bowsher
Journal:  J Pharm Biomed Anal       Date:  2000-01       Impact factor: 3.935

Review 2.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.

Authors:  E Koren; L A Zuckerman; A R Mire-Sluis
Journal:  Curr Pharm Biotechnol       Date:  2002-12       Impact factor: 2.837

3.  Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein.

Authors:  James A Lofgren; Iwona Wala; Eugen Koren; Steven J Swanson; Shuqian Jing
Journal:  J Immunol Methods       Date:  2005-11-28       Impact factor: 2.303

Review 4.  Characterization of an immune response.

Authors:  S J Swanson
Journal:  Dev Biol (Basel)       Date:  2005

5.  An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen.

Authors:  Aaron Patton; Michael C Mullenix; Steven J Swanson; Eugen Koren
Journal:  J Immunol Methods       Date:  2005-09       Impact factor: 2.303

Review 6.  Scientific and regulatory considerations on the immunogenicity of biologics.

Authors:  Gopi Shankar; Elizabeth Shores; Carrie Wagner; Anthony Mire-Sluis
Journal:  Trends Biotechnol       Date:  2006-05-02       Impact factor: 19.536

7.  Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals.

Authors:  David J Snodin; Peter R Ryle
Journal:  BioDrugs       Date:  2006       Impact factor: 5.807

Review 8.  Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.

Authors:  Eugen Koren; Holly W Smith; Elizabeth Shores; Gopi Shankar; Deborah Finco-Kent; Bonita Rup; Yu-Chen Barrett; Viswanath Devanarayan; Boris Gorovits; Shalini Gupta; Thomas Parish; Valerie Quarmby; Michael Moxness; Steven J Swanson; Gary Taniguchi; Linda A Zuckerman; Christopher C Stebbins; Anthony Mire-Sluis
Journal:  J Immunol Methods       Date:  2008-01-29       Impact factor: 2.303

Review 9.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

Authors:  Gopi Shankar; Viswanath Devanarayan; Lakshmi Amaravadi; Yu Chen Barrett; Ronald Bowsher; Deborah Finco-Kent; Michele Fiscella; Boris Gorovits; Susan Kirschner; Michael Moxness; Thomas Parish; Valerie Quarmby; Holly Smith; Wendell Smith; Linda A Zuckerman; Eugen Koren
Journal:  J Pharm Biomed Anal       Date:  2008-09-19       Impact factor: 3.935

10.  Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab.

Authors:  James A Lofgren; Sripriya Dhandapani; Jason J Pennucci; Christina M Abbott; Daniel T Mytych; Arunan Kaliyaperumal; Steven J Swanson; Michael C Mullenix
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

View more
  9 in total

1.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

2.  A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

Authors:  Xiaoying Chen; Timothy Hickling; Eugenia Kraynov; Bing Kuang; Chuenlei Parng; Paolo Vicini
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

Review 3.  Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.

Authors:  Xin Xu; Yulia Vugmeyster
Journal:  AAPS J       Date:  2012-08-04       Impact factor: 4.009

4.  Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics.

Authors:  Lei Zhou; Sarah A Hoofring; Yu Wu; Thuy Vu; Peiming Ma; Steven J Swanson; Narendra Chirmule; Marta Starcevic
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

5.  Comparison of succinimidyl [(125)I]iodobenzoate with iodogen iodination methods to study pharmacokinetics and ADME of biotherapeutics.

Authors:  Jianqing Chen; Mengmeng Wang; Alison Joyce; David DeFranco; Mania Kavosi; Xin Xu; Denise M O'Hara
Journal:  Pharm Res       Date:  2014-05-21       Impact factor: 4.200

6.  Practical application of acid dissociation in monitoring patients treated with adalimumab.

Authors:  Francisca Llinares-Tello; José Rosas-Gómez de Salazar; José Miguel Senabre-Gallego; Gregorio Santos-Soler; Carlos Santos-Ramírez; Esteban Salas-Heredia; Xavier Barber-Vallés; Juan Molina-García
Journal:  Rheumatol Int       Date:  2014-05-10       Impact factor: 2.631

7.  Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.

Authors:  Peter J K van Meer; Marlous Kooijman; Vera Brinks; Christine C Gispen-de Wied; Beatriz Silva-Lima; Ellen H M Moors; Huub Schellekens
Journal:  MAbs       Date:  2013-06-06       Impact factor: 5.857

8.  Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.

Authors:  Diana Mazilu; Daniela Opriş; Cecilia Gainaru; Mihaela Iliuta; Natalia Apetrei; Giorgiana Luca; Andreea Borangiu; Tania Gudu; Alexandra Peltea; Laura Groseanu; Cosmin Constantinescu; Ioana Saulescu; Violeta Bojinca; Andra Balanescu; Denisa Predeteanu; Ruxandra Ionescu
Journal:  Biomed Res Int       Date:  2014-05-20       Impact factor: 3.411

9.  Storage Conditions of Conjugated Reagents Can Impact Results of Immunogenicity Assays.

Authors:  Robert J Kubiak; Nancy Lee; Yuan Zhu; William R Franch; Sophia V Levitskaya; Surekha R Krishnan; Varghese Abraham; Peter F Akufongwe; Christopher J Larkin; Wendy I White
Journal:  J Immunol Res       Date:  2016-07-10       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.